Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-cyclohexyl-N'-(4-Iodophenyl)urea is a synthetic small molecule belonging to the class of phenylureas, specifically an organoiodine compound. Structurally, it consists of a urea core with one nitrogen substituted by a cyclohexyl group and the other by a para-substituted iodophenol group. It is primarily used as an experimental tool compound in biochemical research and has not been approved for medical use. Its main mechanism of action is as an inhibitor of bifunctional epoxide hydrolase 2 (also known as soluble epoxide hydrolase or EPHX2), which plays roles in lipid metabolism and inflammation pathways[2]. There are no known clinical indications or approvals for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-cyclohexyl-N'-(4-iodophenyl)urea.